Table 2. ADA and DPP-IV activity and sCD26 concentration in PE according to gender groups in the study population (mean ± SD).
| All | Men | Women | ||
|---|---|---|---|---|
| ADA activity (UL−1) | Total | 56.2 ± 135.9 (138) | 55.1 ± 140.1 (91) | 58.3 ± 129.0 (47) |
| BPE | 63.7 ± 106.1 (81) | 50.5 ± 48.2 (57) | 91.1 ± 171.8 (24) | |
| +TPE | 75.3 ± 21.4 (30)† | 69.5 ± 15.1 (20) | 86.9 ± 27.7 (10) | |
| +pneumonic* | 90.4 ± 200.1 (21)‡ | 53.6 ± 78.8 (17) | 246.7 ± 439.9 (4) | |
| +paramalignant | 30.7 ± 4.1 (3) | 29.0 ± 4.0 (2) | 34.2 ± 0 (1) | |
| +non neoplastic | 37.1 ± 42.8 (15) | 25.8 ± 9.4 (11) | 53.9 ± 66.6 (4) | |
| +miscellaneous | 26.5 ± 14.0 (12) | 22.8 ± 6.2 (7) | 32.8 ± 22.2 (5) | |
| MPE | 46.1 ± 168.5 (57)∧ | 62.0 ± 215.3 (34) | 21.1 ± 6.1 (23) | |
| +epithelial | 22.7 ± 7.2 (50)∥ | 24.0± 7.8 (28) | 21.1 ± 6.2 (22) | |
| +mesothelioma | 34.4 ± 19.1 (5) | 37.6 ± 20.4 (4) | 21.5 ± 0 (1) | |
| +lymphoma | 686.8 ± 889.8 (2) | 686.8 ± 889.8 (2) | 0 | |
| DPP-IV activity (UL−1) | Total | 45.4 ± 27.19 (140) | 47.9 ± 28.4 (89) | 42.0 ± 25.8 (51) |
| BPE | 41.9 ± 24.0 (80) | 42.9 ± 23.1 (53) | 41.0 ± 27.1 (27) | |
| +TPE | 36.8 ± 12.1 (30) | 37.3 ± 12.9 (20) | 35.8 ± 10.9 (10) | |
| +pneumonic* | 45.3 ± 25.5 (29) | 48.2 ± 26.4 (22) | 36.1 ± 21.6 (7) | |
| +paramalignant | 45.7 ± 17.3 (2) | 33.5 ± 0 (1) | 57.9 ± 0 (1) | |
| +non neoplastic | 40.9 ± 26.7 (10) | 39.6 ± 30.8 (5) | 45.8 ± 35.9 (5) | |
| +miscellaneous | 49.4 ± 41.2 (9) | 47.2 ± 34.4 (5) | 52.1 ± 54.1 (4) | |
| MPE | 50.5 ± 30.8 (60) | 55.4 ± 33.6 (36) | 43.1 ± 24.9 (24) | |
| +epithelial | 47.3 ± 27.7 (54)§ | 50.0 ± 29.5 (31)§ | 43.6 ± 25.3 (23) | |
| +mesothelioma | 60.5 ± 37.0 (4) | 70.1 ± 46.8 (3) | 31.7 ± 0 (1) | |
| +lymphoma | 116.3 ± 10.7 (2) | 116.3 ± 10.7 (2) | 0 | |
| sCD26 concentration (μg L−1) | Total | 337.5 ± 253.1 (159) | 388.5 ± 286.4 (106) | 355.2 ± 165.8 (53) |
| BPE | 360.8 ± 136.1 (92) | 356.1 ± 128.3 (64) | 371.8 ± 154.1 (28) | |
| +TPE | 367.1 ± 113.4 (30) | 357.5 ± 107.7 (20) | 386.4 ± 127.8 (10) | |
| +pneumonic* | 363.1 ± 143.3 (29) | 391.2 ± 119.1 (22) | 274.5 ± 184.7 (7) | |
| +paramalignant | 456.7 ± 176.1 (4) | 422.0 ± 295.6 (2) | 491.4 ± 27.2 (2) | |
| +non neoplastic | 362.5 ± 151.5 (18) | 336.6 ± 142.9 (13) | 429.8 ± 168.4 (5) | |
| +miscellaneous | 300.4 ± 132.2 (11) | 258.9 ± 115.6 (7) | 373.1 ± 143.2 (4) | |
| MPE | 392.8 ± 352.4 (67) | 426.3 ± 421.9 (42) | 336.6 ± 179.4 (25) | |
| +epithelial | 332.8 ± 173.1 (58) | 328.6 ± 168.6 (34) | 338.9 ± 182.9 (24) | |
| +mesothelioma | 990.6 ± 897.6 (6)# | 1132.4 ± 925.5 (5) | 281.8 ± 0 (1) | |
| +lymphoma | 357.0 ± 225.3 (3) | 357.0 ± 225.3 (3) | 0 |
In parentheses (n) number of samples.
*, para and metapneumonic. Interesting statistically significant differences indicated: For ADA;
†U-Mann p < 0.001 between TPE and other groups, except pneumonic PE;
‡U-Mann p < 0.001 between pneumonic PE and other groups except TPE;
∧, T-student p < 0.001 between BPE and MPE;
∥, Kruskal-Wallis ANOVA p < 0.001 for MPE groups. For DPP-IV;
§, U-Mann p = 0.022 (total) and p = 0.029 (men) between MPE epithelial and lymphoma. For CD26;
#, Kruskal-Wallis p < 0.001 for mesotheliomas compared with the other groups.